Abstract
Recently it was shown that the therapeutic efficacy of the anti-CD20 monoclonal antibody rituximab might be influenced by single nucleotide polymorphisms in the Fcγ receptor IIIa gene ( FCGR3A ).[1][1]–[3][2] Binding of the Fc (constant) region of immunoglobulin G1 (IgG1) to the FcGRIIIa on the
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
